Inn Vivo Delayed-Type Hypersensitivity Skin Test Anergy in Human Immunodeficiencyy
Infectionn with human immunodeficiency virus (HIV) induces profoundd defects of cell-mediated immunity, which will eventuallyy result in AIDS. The hallmark of progression of HIV-1 infectionn is depletion of CD4 T cells, but several other surrogate markers,, such as HIV-1 RNA load [1] and T cell reactivity in vitroo [2] , have also been shown to provide important additional informationn regarding the prognosis of HlV-l -infected persons.. Although not frequently used, delayed-type hypersensitivityy (DTH) skin testing was recognized early on as a marker too assess the immune status of HIV-1 -infected persons [3] [4] [5] .
Thee DTH reaction is mediated by Thl cells, which produce interleukin-22 and interferon--y [6] . It has been shown in asymptomaticc HIV-1-infected persons that peripheral blood T cells [7,, 8] and lymph node T cells [9] have a reduced capacity to producee interleukin-2 and interferon-?, which is probably the causee of the diminished capacity to induce DTH reactions. The Thll dysfunction in HIV-1-infected persons could, at least in :ss part, be caused by diminished release of interleukin-12, a cytoi--kine that directs Thl responses [10, 11] and that has been 11 reported as able to restore HIV-specific T cell responses in ee patients [12, 13] . nn DTH anergy (DTHA) has been observed in 20%-30% [14, ill 15] of asymptomatic HIV-1-infected persons with normal or r--slightly decreased CD4 T cell counts. The prognostic signifii--cance of DTH A has been recognized in the Walter Reed classierr fication, in which it was an independent indicator for progres-].. sion to disease [16] [17] [18] . :ee
We therefore investigated the possible relation between )--DTHA and T cell function in vitro by using different stimulalss tion protocols, as well as the wider association with the other :oo virologie and immunologic markers used for monitoring proiee gression of HIV-1 infection, ie e in n Materialss and Methods
__
Study population. The study population consisted of HIV-1 -infectedd white homosexual men who were participating in the Amsterdamm Cohort study on HIV infection and AIDS [19] . Particintt pants were seen at 3-month intervals. At each 3-monthly visit, as <** well as a physical examination and a medical history, immunologic andd virologie laboratory evaluations were done. jJDD A multitest cellular-mediated immunity (CMI) skin test was ;e ,, done on all 136 HIV-1-infected participants who visited the Municipall Health Service in the period from September 1995 through ** February 1996, at one of the routine visits or shortly afterwards.
188
DTH skin testing. For evaluation of DTHA, we used the commerciallyy available Multitest CMI applicator (Institut Mérieux, Lyon,, France) {20-22]. The recall antigens applied with the multitestt were tetanus, diphtheria, Streptococcus group C, tubercuInn a cross-sectional study, the prevalence of delayed-type hypersensitivity skin test anergy (DTHA) wass examined in 136 asymptomatic human immunodeficiency virus-infected participants in relation too immunologic and virologie parameters. DTHA was assessed with a multitest cell-mediated immunityy skin test. Of the 136 participants, with a mean CD4 T cell count of 335 x 10*/L, 25 were anergicc (18.4%). In the stepwise forward multivariate logistic regression models, after adjustment forr CD4 T cell counts, depending on whether it was analyzed continuously or after dichotomization (20thh percentile), both T cell reactivity to CD2 plus CD28 antibodies or to CD3 antibodies were the mostt predictive markers of DTHA (odds ratio, 0.80; 95% confidence interval, 0.67-0.94; and odds ratio,, 2.97; 95% confidence interval, 1.1-8.3, respectively). This study shows a strong correlation betweenn the decreased T ceil responses in vitro and DTHA. Therefore, next to DTHA testing, T celll function assays may be useful to test immune reconstitution observed during ant [retroviral treatment. . lin,, Proteus, Candida albicans, and Trichophyton along with a glycerinee control. The result of the skin test was assessed after 48 h.. The test was administered and interpreted by trained nurses [23] off the tuberculosis prevention department of the Municipal Health Servicee of Amsterdam. Furthermore, for a reference, the multitest wass also applied to 20 staff members of the Municipal Health Servicee of Amsterdam and to 4 HIV-negative homosexual men. Noo blood was drawn from these controls. DTHA is frequently definedd as none of the skin test indurations >2 mm [24] . However, thiss definition was not feasible because the number of anergic personss was too small to perform an analysis. Therefore, the followingg DTHA definition was used: A skin induration 3*2 mm to ann individual recall antigen was considered a response. The mean DTHH score was defined as the sum of all of the indurations 5*2 mmm (nominator), divided by the number of responding antigens (denominator).. DTHA was defined as a mean DTH score «2 mm.
LaboratoryLaboratory methods. Sera were tested for the presence of HI V-11 antibodies with two commercially available ELISAs (Abbott Laboratories,, Abbott Park, IL; Vironostika Teknika, Organon, Oss, Thee Netherlands) and confirmed with Western blot. HIV-1 p24 antigenn was detected with a solid-phase, sandwich-type EIA (Abbottt Laboratories). The HIV-1 RNA virus load was assessed with thee nucleic acid sequence-based amplification [25] assay in cryopreservedd sera. All serologic and immunologic tests were carried outt in fresh specimens. T cell subsets were enumerated by a direct immunofluorescentt technique using monoclonal antibodies (MAbs)) and a flow cytometry system. Cocultivation of peripheral bloodd mononuclear cells with MT-2 cells was used to detect the presencee of syncytium-inducing HIV-1 variants [26] . To measure TT cell reactivity, fresh cells were stimulated in a whole blood culturee system with CD3 MAb, CD3 plus CD28 MAb [27] , CD2 pluss CD28 MAb, and phytohemagglutinin [28] , Reactivity was expressedd as the percentage of median responses detected in concurrentlyy running cultures of 5 healthy controls.
StatisticalStatistical analysis. In a cross-sectional design, continuous variabless with an approximately normal distribution were tested withh Student's / test. Variables with a skewed distribution were testedd with the Mann-Whitney test or, after the most appropriate transformationn (log or square root), tested with the Student's t test. Inn addition, categorical variables were examined with the x 2 'est. Thee predictive value for developing DTHA was assessed in two ways,, continuously and after dichotomization. In the latter analysis, thee continuous variables were dichotomized at the 20th percentile. Thiss level was chosen because it approximates the lower reference rangee that is used by our laboratory. In this analysis, the odds ratio (OR)) of DTHA was calculated in the group with marker levels beloww the 20th percentile compared with others in the study group (ss20thh vs. >20th percentile). Plasma HIV-1 RNA vims load was log-transformed,, and the dichotomization threshold was set at 10* copies/mL,, the level at which antiretroviral treatment is recommendedd [1] .
ORss with 95% confidence intervals (95% CIs) were calculated withh logistic regression. The associations between the presence of DTHAA and the various immunologic and virologie variables were analyzedd univariately and after adjustment for CD4 T cell count. Finally,, the variables that predicted DTHA significantly were analyzedd in a stepwise forward model. The following levels of significancee were used: P 3= .10 for removal and P < .10 for addition.
Results s
Thee mean age of the 136 HIV-1-positive homosexual men wass 41.5 years (range, 25-59). Ninety-four were HIV-1-positivee at entry and 42 seroconverted during follow-up. The mean HIV-positivee follow-up period was 6.4 years, with a range of 33 months to 11 years. The mean age of the 24 controls (15 menn and 9 women) was 41 years (range, 28-56). In 60% of subjects,, time between blood drawing at one of the routine visitss and applying the multitest was <2 weeks, with a maximumm range of 3 months.
Off the 136 HIV-1-positive men included in this study, 25 weree found to be anergic (18.4%), compared with 1 in the controll group (4.2%) (P = .13). However, the sum of skin test indurations,, the number of responding antigens per subject, andd the mean DTH score were all significantly lower in the HIV-11 -positive subjects than in controls (P < .001, P < .001 [figuree 1], and P = .002, respectively). Eleven subjects showed noo response whatsoever against any of the antigens (8%), comparedd with none of the controls (P = .16).
Tablee 1 shows that the mean induration and the percentage of respondingg subjects per recall antigen was in general lowerexceptt for Trichophyton antigen-in the HIV-1-infected groupp than in the control group, although statistical significance wass not always reached.
Thee HIV-1-infected subjects were divided into 2 groups, anergicc (n = 25) and responders (n = 111), and compared regardingregarding virologie and immunologic markers (table 2). The meann CD4 T cell count for the 136 HIV-1 -positive participants wass 335 X 10 6 /L, with a mean for responders and anergic men off 355 X 10 6 /L and 246 X 10 6 /L, respectively (P = .01). Moreover,, T cell responses induced by CD3 MAb, CD3 plus CD288 MAb, and CD2 plus CD28 MAb were significantly higherr in the responders than in the anergic men. Of the virologiee markers, only HIV-1 p24 antigen differed significantly betweenn the groups. Plasma HIV-1 RNA virus load did not. Theree was no association of DTHA with age or length of follow-upp (P = .37 and .67, respectively).
Inn the univariate logistic regression analysts, the following continuouss markers were shown to be significantly associated withh DTHA (table 3): CD4 T cell count and low T cell reactivityy after stimulation with CD3 plus CD28 MAb and CD2 plus CD288 MAb. The presence of HIV-1 p24 antigen was also significantlyy associated with DTHA. In the stepwise forward multivariatee model (including CD4 T cell count, T cell reactivityy after stimulation with CD3 plus CD28 MAb and CD2 plus CD288 MAb, and HIV-1 p24 antigen), low T cell reactivity afterr stimulation with CD2 plus CD28 MAb appeared to be thee most predictive marker, with an OR of 0.80 (95% CI, 0.67-0.95)) (P = .01).
Inn the univariate logistic regression analysis, the following dichotomizedd markers were shown to be significantly associatedd with DTHA (table 3): low T cell reactivity after stimulationn with CD3 MAb and CD2 plus CD28 MAb. In a bivariate analysiss with CD4 T cell count forced into the logistic model, thee ORs for the other markers remained similar. In the final stepwisee forward multivariate model, including CD3 MAb, CD22 plus CD28 MAb, and HIV-1 p24 antigen, low T cell reactivityy to CD3 MAb appeared to be the best discriminating marker,, with an OR of 2.97 (95% CI, 1.1-8.3) [P = .04). Furthermore,, we performed a third logistic analysis in which wee defined DTHA as none of the indurations >2 mm (11 anergicc men vs. 125 responders). In this analysis, low T cell reactivityy to CD2 plus CD28 MAb appeared to be the strongest predictorr of DTHA, with an OR of 3.0 (95% CI, 0.8-11.9) (P == Discussion n Increasingly,, sets of progression markers are being used to stagee HIV-1-infected patients. Most of these surrogate markers,, for example, plasma HIV-1 RNA load and CD4 T cell count,, have proven to be useful as predictors of progression to symptomaticc HIV-1 infection and death. DTH skin induration [29] demonstratedd that DTHA is an independent marker for progressionn to AIDS. DTHA can therefore be useful in distinguishing progressorss from nonprogressors in the group of HIV-1 -infectedd asymptomatic persons.
Dependingg on whether analyses were done with continuous variabless or after dichotomization, we found a strong associationn between DTHA and depressed T cell responsiveness to activationn signals induced by CD2 plus CD28 MAb or CD3 MAb.. However, T cell reactivity after stimulation with CD2 pluss CD28 MAb appeared to be a more universal predictor of DTHAA than was T cell reactivity after stimulation with CD3 MAb.. This can be explained by the fact that, in addition to activationn via the CD3 T cell receptor complex or the CD2 T celll receptor, CD28 MAb delivers a second signal to T cells [27] .. In vitro, the CD28 MAb, not being mitogenic on its own, stronglyy enhances proliferation of T cells stimulated by CD3 MAbb or CD2 MAb. Therefore, in patients with more advanced HIVV infection, T cell reactivity to CD2 plus CD28 MAb is longerr preserved and more robust than T cell reactivity to CD3 MAb. . Althoughh a significant association between DTHA and HIV p244 antigen was found, surprisingly, no association with plasma HIV-11 RNA at the level of 10,000 copies/mL could be found. However,, if a higher cutoff value was used, the plasma HIV RNAA level became more predictive (data not shown). From thiss we have concluded that HIV RNA is only capable of predictingg DTHA at higher RNA levels.
Inn previous studies, we have demonstrated that early in infection,, CD3 MAb-induced T cell responses are depressed in Tablee Wee and others previously showed improved T cell function, onn a per-cell basis, in zidovudine-treated patients [32] and in patientss treated with combination therapy [33, 34] . From this, wee conclude that T cell reactivity in vitro can be useful for determiningg effectiveness of antiretroviral treatment and the extentt of in vivo immune reconstitution.
Inn summary, to our knowledge, this is the first study to examinee the direct relationship between DTH skin tests and thee various virologie and immunologic in vitro markers of progressionn of HIV. We found, independent of CD4 T cells, associationss between DTHA and T cell reactivity to CD3 MAb andd CD2 plus CD28 MAb. For a more intensive monitoring off cellular immunity, determination of T cell reactivity in vitro, nextt to CD4 T cells and HIV-1 RNA load, may be included.
